A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor

Journal of Virology

Volumn 73, Issue 11, 1999, Pages 8966-8974

  Trkola, Alexandra ^a,b   Matthews, Jamie ^a   Gordon, Cynthia ^a   Ketas, Tom ^a   Moore, John P ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ARTICLE; CELL DIVISION; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPOTHESIS; IMMUNE RESPONSE; MONKEY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS CULTURE; VIRUS ISOLATION;

EID: 0032828730     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.11.8966-8974.1999     Document Type: Article

References (78)

1. Alkhatib, G., C. Combadiere, C. C. Broder, Y. Feng, P. E. Kennedy, P. M. Murphy, and E. A. Berger. 1996. CC CKR5: a RANTES, MIP-1α, MIP-lß receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955-1958.
2. Allaway, G. P., K. L. Davis-Bruno, G. A. Beaudry, E. B. Garcia, E. L. Wong, A. M. Ryder, K. W. Hasel, M.-C. Gauduin, R. A. Koup, J. S. McDougal, and P. J. Maddon. 1995. Expression and characterization of CD4IgG2, a novel heterotetramer which neutralizes primary HIV-1 isolates. AIDS Res. Hum. Retroviruses 11:533-540.
3. Berger, E. A., R. W. Doms, E.-M. Fenyö, B. T. M. Korber, D. R. Littman, J. P. Moore, Q. J. Sattentau, H. Schuitemaker, J. Sodroski, and R. A. Weiss. 1998. A new classification for HIV-1. Nature 391:240.
4. Bleul, C. C., L. Wu, J. A. Hoxie, T. A. Springer, and C. R. Mackay. 1997 The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. USA 94:1925-1930.
5. Burton, D. R. 1997. A vaccine for HIV type 1 : the antibody perspective. Proc. Natl. Acad. Sci. USA 94:10018-10023.
6. Burton, D. R., and D. C. Montefiori. 1997. The antibody response in HIV-1 infection. AIDS 11(Suppl. A):587-598.
7. Burton, D. R., and J. P. Moore. 1998. Why do we not have an HIV vaccine and how can we make one? Nat. Med. 4:495-498.
8. Castro, B., C. Weiss, L. Wiviott, and J. Levy. 1988. Optimal conditions for recovery of the human immunodeficiency virus from peripheral blood to mononuclear cells. J. Clin. Microbiol. 26:2371-2376.
9. Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P. D. Ponath, L. Wu, C. R. Mackay, G. LaRosa, W. Newman, N. Gerard, G. Gerard, and J. Sodroski. 1996. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148.
10. Chuck, A. S., and B. O. Palsson. 1996. Consistent and high rates of gene transfer can be obtained using flow-through transduction over a wide range of retroviral titers. Hum. Gene Ther. 7:743-750.
11. Daar, E. S., X. L. Li, T. Moudgil, and D. D. Ho. 1990. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. USA 87:6574-6578.
12. Deng, H., D. Unutmaz, V. N. Kewalramani, and D. R. Littman. 1997. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 388:296-300.
13. Donzella, G. A., D. Schols, S. W. Lin, J. A. Esté, K. A. Nagashima, P. J. Maddon, G. P. Allaway, T. P. Sakmar, G. Henson, E. De Clercq, and J. P. Moore. 1998. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 4:72-77.
14. Duranz, B. J., K. Grovit-Ferbas, M. P. Sharron, S.-H. Mao, M. B. Goetz, E. S. Daar, R. W. Doms, and W. A. O'Brien. 1997. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med. 186:1395-1400.
15. Doranz, B. J., J. Rucker, Y. Yi, R. J. Smyth, M. Samson, S. Peiper, M. Parmentier, R. G. Collman, and R. W. Doms. 1996. A dual-tropic, primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-2b as fusion cofactors. Cell 85:1149-1159.
16. Dorsky, D. I., M. Wells, and R. D. Harrington. 1996. Detection of HIV-1 infection with a green fluorescent protein reporter system. J. Acquired Immune Defic. Syndr. 13:308-313.
17. Dragic, T., V. Litwin, G. P. Allaway, S. R. Martin, Y. Huang, K. A. Nagashima, C. Cayanan, P. J. Maddon, R. A. Koup, J. P. Moore, and W. A. Paxton. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CK.R-5. Nature 381:667-673.
18. Edinger, A. L., T. L. Hoffman, M. Sharron, B. Lee, B. O'Dowd, and R. W. Doms. 1998. Use of GPR1, GPR15, and STRL33 as co-receptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins. Virology 249:367-378.
19. Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G protein coupled receptor. Science 272:872-877.
20. Gauduin, M.-C., P. W. Parren, R. Weir, C. F. Barbas, D. R. Burton, and R. A. Koup. 1997. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat. Med. 3:1389-1393.
21. Gervaix, A., D. West, L. M. Leoni, D. D. Richman, and F. Wong-Staal. 1997. A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc. Natl. Acad. Sci. USA 94:4653-4658.
22. Haynes, B. F., G. Pantaleo, and A. S. Fauci. 1996. Towards an understanding of the correlates of protective immunity to HIV infection. Science 271:324-328.
23. Heilman, C. A., and D. Baltimore. 1998. HIV vaccines - where are we going? Nat. Med. 4:532-534.
24. Hilleman, M. R. 1998. A simplified vaccinologist's vaccinology and the pursuit of a vaccine against AIDS. Vaccine 16:778-793.
25. Howell, D. N., P. E. Andreotti, J. R. Dawson, and P. Cresswell. 1985. Natural killing target antigens as inducers of interferon: studies with an immuno-selected, natural killing-resistant human T lymphoblastoid cell line. J. Immunol. 134:971-976.
26. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66:3026-3031.
27. Konopka, K., L. Stamatatos, C. Larsen, B. Davis, and N. Duzgunes. 1991. Enhancement of human immunodeficiency virus type 1 infection by cationic liposomes: the role of CD4, serum and liposome-cell interactions. J. Gen. Virol. 72:2685-2696.
28. Kozak, S. L., and D. Kabat. 1990. Ping-pong amplification of a retroviral vector achieves high-level gene expression: human growth hormone production. J. Virol. 64:3500-3508.
29. Kozak, S. L., E. J. Platt, N. Madani, F. E. Ferro, Jr., K. Peden, and D. Kabat. 1997. CD4, CXCR-4, and CCR-5 dependencies for infection by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J. Virol. 71:873-882.
30. LaCasse, R. A., K. E. Follis, T. Moudgil, M. Trahey, J. M. Binley, V. Planelles, S. Zolla-Pazner, and J. H. Nunberg. 1998. Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity. J. Virol. 72:2491-2495.
31. Lee, B., M. Sharron, L. J. Montaner, D. Weismaan, and R. W. Doms. 1999. Quantification of CD4, CCR5 and CXCR4 levels on lymphocyte subsets, dendritic cells, and differently conditioned monocyte derived macrophages. Proc. Natl. Acad. Sci. USA 96:5215-5220.
32. Letvin, N. L. 1998. Progress in the development of an HIV-1 vaccine. Science 280:1875-1880.
33. Letvin, N. L. 1998. What immunity can protect against HIV infection? J. Clin. Investig. 102:1643-1644.
34. + T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J. Virol. 69:3712-3720.
35. Mann, R., R. C. Mulligan, and D. Baltimore. 1983. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33:153-159.
36. Markowitz, M., M. Vesanen, K. Tenner-Racz, Y. Cao, J. M. Binley, A. Talal, A. Hurley, X. Jin, M. R. Chaudhry, M. Yaman, M. Heath-Chiozzi, J. M. Leonard, J. P. Moore, P. Racz, D. F. Nixon, and D. D. Ho. 1999. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on virus replication and antiviral immune responses. J. Infect. Dis. 179:525-537.
37. Mascola, J. R., M. G. Lewis, G. Stiegler, D. Harris, T. C. VanCott, D. Hayes, M. K. Louder, C. R. Brown, C. V. Sapan, S. S. Frankel, Y. Lu, M. L. Robb, H. Katinger, and D. L. Birx. 1999. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:4009-4018.
38. Miller, A. D., M. F. Law, and I. M. Verma. 1985. Generation of helper-free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reductase gene. Mol. Cell. Biol. 5:431-437.
39. Mo, H., S. Monard, H. Pollack, J. Ip, G. Rochford, L. Wu, J. Hoxie, W. Borkowsky, D. D. Ho, and J. P. Moore. 1998. Expression patterns of the HIV type 1 co-receptors CCR5 and CXCR4 on CD4+ T-cells and monocytes from cord and adult blood. AIDS Res. Hum. Retroviruses 14:607-618.
40. Mondor, I., S. Ugolini, and Q. J. Sattentau. 1998. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J. Virol. 72:3623-3634.
41. Montefiori, D. C., R. G. Collman, T. R. Fouts, J. Y. Zhou, M. Bilska, J. A. Hoxie, J. P. Moore, and D. P. Bolognesi. 1998. Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. J. Virol. 72: 1886-1893.
42. Montefiori, D. C., and T. G. Evans. 1999. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. AIDS Res. Hum. Retroviruses 15:689-698.
43. Moog, C., H. J. A. Fleury, I. Pellegrin, A. Kirn, and A. M. Aubertin. 1997. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J. Virol. 71:3734-3741.
44. Moore, J. P., and D. R. Burton. 1999. HIV-1 neutralizing antibodies: how full is the bottle? Nat. Med. 5:142-144.
45. Moore, J. P., Y. Cao, L. Qing, Q. J. Sattentau, J. Pyati, R. Koduri, J. Robinson, C. F. Barbas III, D. R. Burton, and D. D. Ho. 1995. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120 and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:101-109.
46. Moore, J. P., and D. D. Ho. 1995. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 9(Suppl. A):S117-S136.
47. Moore, J. P., J. A. McKeating, R. A. Weiss, and Q. J. Sattentau. 1990. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 250:1139-1142.
48. Morgan, J. R., J. M. LeDoux, R. G. Snow, R. G. Tompkins, and M. L. Yarmush. 1995. Retrovirus infection: effect of time and target cell number. J. Virol. 69:6994-7000.
49. Murakami, T., T. Nakajima, Y. Koyanagi, K. Tachibana, N. Fujii, H. Tamamura, N. Yoshida, M. Waki, A. Matsumoto, O. Yoshie, T. Kishimoto, N. Yamamoto, and T. Nagasawa. 1997. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J. Exp. Med. 186:1389-1393.
50. Muster, T., R. Guinea, A. Trkola, M. Purtscher, A. Klima, F. Steindl, P. Palese, and H. Katinger. 1994. Cross-neutralizing antibodies against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 68:4031-4034.
51. Orloff, G. M., S. L. Orloff, M. S. Kennedy, P. J. Maddon, and J. S. McDougal. 1991. Penetration of CD4 T cells by HIV-1. The CD4 receptor does not internalize with HIV, and CD4-related signal transduction events are not required for entry. J. Immunol. 146:2578-2587.
52. Ortiz, G. M., D. F. Nixon, A. Trkola, J. Binley, X. Jin, S. Bonhoeffer, P. J. Kuebler, S. M. Donahoe, M.-A. Demoitie, W. M. Kakimoto, T. Ketas, B. Clas, L. Zhang, Y. Cao, A. Hurley, J. P. Moore, D. D. Ho, and M. Markowitz. 1999. Temporary containment of HIV-1 replication following discontinuation of HAART is associated with strong virus-specific immune responses. J. Clin. Investig. 104:R13-R18.
53. Parren, P. W. H. I., J. P. Moore, D. R. Burton, and Q. J. Sattentau. 1999. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 13(Suppl. A):S137-S162.
54. Perelson, A., A. U. Neumann, M. Markowitz, J. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
55. Platt, E. J., N. Madiani, S. L. Kozak, and D. Rabat. 1997. Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor. J. Virol. 71:883-890.
56. Poignard, P., R. Sabbe, G. R. Picchio, M. Wang, R. J. Gulizia, H. Katinger, P. W. H. I. Parren, D. E. Mosier, and D. R Burton. 1999. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 10:431-438.
57. Poret, C. D., K. V. Lukacs, G. Box, Y. Takeuchi, and M. K. L. Collins. 1998. Cationic liposomes enhance the rate of transduction by a recombinant retroviral vector in vitro and in vivo. J. Virol. 72:4832-4840.
58. Rabin, R. L., M. K. Park, F. Liao, R. Swofford, D. Stephany, and J. M. Farber. 1999. Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J. Immunol. 162:3840-3850.
59. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27:493-497.
60. Schols, D., S. Struyf, J. Van Damme, J. A. Esté, G. Henson, and E. De Clerq. 1997. Inhibition of T-tropic HIV strains by selective antagonization of the Chemokine receptor CXCR4. J. Exp. Med. 186:1383-1388.
61. Shibata, R., T. Igarashi, N. Haigwood, A. Buckler-White, R. Ogert, W. Ross, R. Willey, M. W. Cho, and M. A. Martin. 1999. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV 1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5:204-210.
62. Spenlehauer, C., S. Saragosti, H. J. A. Fleury, A. Kirn, A.-M. Aubertin, and C. Moog. 1998. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1. J. Virol. 72:9855-9864.
63. Springer, T. A. 1990. Adhesion receptors of the immune system. Nature 346:425-434.
64. Sullivan, N., Y. Sun, J. Li, W. Hofmann, and J. Sodroski. 1995. Replicative function and neutralization sensitivity of envelope glycoprotein from primary and T-cell line-passaged human immunodeficiency virus type isolates. J. Virol. 69:4413-4422.
65. Toyoshima, K., and P. Vogt. 1969. Enhancement and inhibition of avian sarcoma virus by polycations and polyanions. Virology 38:414-426.
66. Trkola, A., T. Ketas, V. N. Kewalramani, F. Endorf, J. M. Binley, H. Katinger, J. Robinson, D. R. Liftman, and J. P. Moore. 1998. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J. Virol. 72:1876-1885.
67. Trkola, A., W. A. Paxton, S. P. Monard, J. A. Hoxie, M. A. Siani, D. A. Thompson, L. Wu, C. R. Mackay, R. Horuk, and J. P. Moore. 1998. Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines. J. Virol. 72:396-404.
68. Trkola, A., A. B. Pomales, H. Yuan, B. Korber, P. J. Maddon, G. P. Allaway, H. Katinger, C. F. Barbas III, D. R. Burton, D. D. Ho, and J. P. Moore. 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69:6609-6617.
69. Van Cott, T. C., V. R. Polonis, L. D. Loomis, N. L. Michael, P. L. Nara, and D. L. Birx. 1995. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory adapted isolates of HIV-1. AIDS Res. Hum. Retroviruses 11:1379-1392.
70. Vodicka, M. A., W. C. Goh, L. I. Wu, M. E. Rogel, S. R. Bartz, V. L. Schweickart, C. J. Raport, and M. Emerman. 1997. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 233:193-198.
71. Wang, H., R. Paul, R. E. Burgeson, D. R. Keene, and D. Kabat. 1991. Plasma membrane receptors for ecotropic murine retroviruses require a limiting accessory factor. J. Virol. 65:6468-6477.
72. Wrin, T., T. P. Loh, J. C. Vennari, H. Schuitemaker, and J. H. Nunberg. 1995. Adaptation to growth in the H9 cell line renders a human immuno-deficiency virus type 1 sensitive to neutralization by vaccine sera. J. Virol. 69:39-48.
73. Wu, L., G. LaRosa, N. Kassam, C. J. Gordon, H. Heath, N. Ruffing, H. Chen, J. Humblias, M. Samson, M. Parmentier, J. P. Moore, and C. R. Mackay. 1997. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. 186:1373-1381.
74. Wu, L., W. A, Paxton, N. Kassam, N. Ruffing, J. B. Rottman, N. Sullivan, H. Choe, J. Sodroski, W. Newman, R. A. Koup, and C. Mackay. 1997. CCR5 levels and expression pattern correlate with infectability by macrophage tropic HIV-1, in vitro. J. Exp. Med. 185:1681-1691.
75. Zhang, Y.-J., T. Dragic, Y. Cao, L. Kostrikis, D. S. Kwon, D. R. Littman, V. N. Kewalramani, and J. P. Moore. 1998. Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J. Virol. 72:9337-9344.
76. Zhang, Y.-J., and J. P. Moore. 1999. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1? J. Virol. 73:3443-3448.
77. Zhou, J. Y., and D. C. Montefiori. 1997. Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells. J. Virol. 71:2512-2517.
78. Zolla-Pazner, S., and S. Sharpe. 1996. A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates. AIDS Res. Hum. Retroviruses 11:1449-1458.